Target intelligence / Profile preview

Adipocyte differentiation pathways

Molecular classification
Other (Cellular pathway)
01

Overview

Adipocyte differentiation pathways describe the complex network of signaling cascades and transcriptional programs that mediate the process by which mesenchymal stem cells become mature adipocytes. Essential steps include two phases: the commitment phase (where stem cells are restricted to the adipocyte lineage) and the differentiation phase (where preadipocytes undergo mitotic expansion and subsequent morphological changes, culminating in lipid accumulation). Key molecules include transcription factors such as PPARγ (the master regulator), CCAAT/enhancer-binding proteins (C/EBPs), and other families like Kruppel-like factors (KLFs). Pathways such as PI3K-Akt, MAPK, Hedgehog, Notch, TGF-β, Wnt, and insulin signaling can promote or inhibit the differentiation process, and epigenetic modification (e.g., DNA methylation) may also play a critical role. These pathways are implicated in metabolic health and diseases like obesity, diabetes, and cancer, and are of interest for therapeutic interventions. This entry does not correspond to a single molecular entity but encompasses a broad set of mechanisms and molecules; individual targets within these pathways (such as PPARγ or C/EBPα) are potential canonical therapeutic targets.

Other names
Adipogenesis pathwaysFat cell differentiation pathwaysAdipogenic signaling pathways
02

Mechanism of action

Activation of PPARγ (a master regulator nuclear receptor promotes adipocyte gene expression); Modulation of C/EBP family transcription factors (controls gene expression relevant to adipogenesis); Inhibition or activation of signaling cascades such as PI3K-Akt, Wnt, TGF-β, Hedgehog, MAPK

03

Biological functions

Cell differentiationSignal transductionMetabolic regulationCell proliferationCell cycleApoptosisEpigenetic regulation
04

Disease associations

ObesityCancerCardiovascular diseaseType 2 diabetes mellitusMetabolic syndrome
05

Safety considerations

Off-target effects (due to broad involvement in metabolism and cell proliferation)Risk of promoting obesity or metabolic disorders if pathways are dysregulatedPotential cardiovascular risk from some PPARγ-activating drugs
06

Interacting drugs

Thiazolidinediones (e.g., pioglitazone, rosiglitazone)

2 more in the full profile.

07

Biomarkers

PPARγ expressionC/EBPα/β expressionAdiponectinFatty acid-binding protein 4 (FABP4)

Beyond the preview

Go deeper on Adipocyte differentiation pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adipocyte differentiation pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call